Johnson & Johnson Pty Ltd
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson.
We embrace science and medical research – bringing the latest ideas, products and services to advance the health and well-being of people around the world.
Our family of companies
- The world’s premier consumer health company;
- The world’s largest and most diverse medical devices and diagnostics company;
- The world’s fifth-largest biologics company; and
- The world’s eighth-largest pharmaceuticals company.
Employees of the Johnson & Johnson Family of Companies work with partners in healthcare to touch the lives of over a billion people every day, around the world.
We have more than 275 operating companies in more than 60 countries employing approximately 128,700 people.
For the past five years, we’ve consistently invested over 11 percent of sales to support our R&D efforts. This equates to over US$8 billion enterprise-wide in 2013. Our investments in R&D are helping us continually deliver meaningful innovations for our customers. About 25 percent of our sales have come from products we have introduced in just the past five years.
Johnson & Johnson see our citizenship and sustainability as more than our social, environmental and economic performance. Rather, it is who we are and how we act. It is how we lead and participate in helping solve the world’s major healthcare challenges, protecting the environment and conserving resources we are privileged to use. It is how we conduct ourselves and our business to contribute positively to society.
We have contributed nearly US$1 billion in funds and products to support 600 programs in 50 countries in 2013. A number of these are in Australia and neighbouring countries, and include Careflight, Barnardos, Operation Smile and Interplast. We also provide a broad base of strong support to the Salvation Army, St Vincent de Paul and Mary MacKillop East Timor Mission to make a positive difference in the community.
Johnson & Johnson Pty Ltd became an Australian entity in 1931.
Today, around 2000 people are employed by the Johnson & Johnson Family of Companies in Australia and New Zealand, and revenue from continuing operations is AUD$1.5bn.
There are four health and medical care-focused operating companies in Australia: Johnson & Johnson Medical, Janssen, Johnson & Johnson Pacific and Tasmanian Alkaloids.
Johnson & Johnson Pacific
Johnson & Johnson Pacific Pty Ltd (JJP) is the largest over-the-counter supplier to retail Pharmacy in Australia serving over 4500 community pharmacies and ranking in the top five Health & Beauty suppliers to Australian Grocery.
We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. With our broad reach, JJP touches millions of consumers’ lives every day. In fact, a JJP product is present in 7-out-of-10 Australian households. Many of our brands, including CODRAL®, SUDAFED® LISTERINE® Mouthwash, BAND-AID® Brand Adhesive Bandages, REGAINE®, NEUTROGENA® and JOHNSON’S® baby toiletries are #1 in the categories in which they compete. These brands bring value to people’s daily lives, while our innovations in areas such as smoking cessation and sun protection are helping to advance the prevention of disease in the Australian population.
Devices & diagnostics
Johnson & Johnson Medical Companies
Our Medical Devices and Diagnostics (MD&D) business employs approximately 600 people in Australia. The business produces a broad range of innovative products and solutions used primarily by health care professionals in the fields of general surgery, orthopaedics, neurological disease, bariatric surgery, infection prevention, diagnostics, cardiovascular disease, and aesthetics.
The Johnson & Johnson MD&D business has more than 30 major new products undergoing a regulatory submission in the next two years. These products will further improve patient outcomes and expand our market leadership while facilitating the development of new business models. MD&D innovation is intended to help customers improve clinical outcomes, increase patient satisfaction and contain costs.
Janssen-Cilag Pty Ltd (Janssen) employs 340 people in Australia and New Zealand passionate about addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer); immunology (e.g. ulcerative colitis, Crohn’s disease and psoriasis); neuroscience (e.g. schizophrenia); infectious disease (e.g. HIV/AIDS and Hepatitis C); and cardiovascular and metabolic diseases (e.g. diabetes).
We have a proud heritage in our founder Dr Paul Janssen who established the company with a strong grounding in science and innovative solutions. Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.
Tasmanian Alkaloids Pty Ltd is an advanced agricultural production and R&D company located in Westbury, near Launceston. It extracts alkaloids used in the manufacture of opiate-based pain-control medicines from poppy straw. Around 99% of this product is exported, making Tasmanian Alkaloids the largest manufacturer of active pharmaceutical ingredients in Australia, supplying 45-50% of the world’s demand for medicinal opiates.
Tasmanian Alkaloids contracts with approximately 530 Tasmanian farmers to grow the poppy crop, and 50 additional contractors also linked to the agricultural operations. Export earnings of about AUD$170 million flow through the company to the Tasmanian economy with a multiplier effect of five times.
For more information, please visit: http://www.jnjmedical.com.au/.